Profile data is unavailable for this security.
About the company
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The Company encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.
- Revenue in USD (TTM)0.00
- Net income in USD-4.03m
- Incorporated2005
- Employees3.00
- LocationLixte Biotechnology Holdings IncNo. 2, 248 Route 25AEAST SETAUKET 11733United StatesUSA
- Phone+1 (310) 203-2902
- Fax+1 (928) 982-5050
- Websitehttps://lixte.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Matinas BioPharma Holdings Inc | 0.00 | -22.91m | 3.49m | 32.00 | -- | 0.1827 | -- | -- | -5.10 | -5.10 | 0.00 | 3.81 | 0.00 | -- | -- | 0.00 | -78.48 | -44.62 | -85.80 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.001 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -28.37m | 3.60m | 22.00 | -- | 1.93 | -- | -- | -6.49 | -6.49 | 0.00 | 0.6142 | 0.00 | -- | -- | 0.00 | -133.45 | -61.43 | -167.53 | -68.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Silexion Therapeutics Corp | 0.00 | -523.87k | 3.63m | 0.00 | -- | 0.4001 | -- | -- | -0.1403 | -0.1403 | 0.00 | 0.6559 | 0.00 | -- | -- | -- | -3.13 | -- | -3.77 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.96 | -- | -- | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 3.65m | 0.00 | -- | 1.96 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| Therapeutic Solutions International Inc | 91.38k | -2.00m | 3.66m | 3.00 | -- | 2.66 | -- | 40.09 | -0.0005 | -0.0005 | 0.00002 | 0.0003 | 0.0252 | 1.29 | 5.24 | 30,460.00 | -63.67 | -162.32 | -153.29 | -- | 65.18 | 67.79 | -2,530.31 | -2,391.85 | 0.3883 | -6.94 | 0.3164 | -- | -52.13 | 95.35 | 43.11 | -- | -- | -- |
| TNF Pharmaceuticals Inc | 0.00 | -7.07m | 3.69m | 9.00 | -- | 0.1367 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -10.44m | 3.71m | 5.00 | -- | 0.5085 | -- | -- | -3.33 | -3.33 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -82.83 | -- | -88.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -25.25m | 3.72m | 40.00 | -- | 0.2529 | -- | -- | -46.21 | -45.63 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -115.20 | -47.16 | -160.28 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| Oncternal Therapeutics Inc | 1.85m | -35.97m | 3.76m | 27.00 | -- | 0.2386 | -- | 2.04 | -12.19 | -12.19 | 0.6254 | 5.32 | 0.0495 | -- | -- | 68,370.37 | -96.40 | -49.40 | -116.52 | -54.51 | -- | -- | -1,948.70 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Chromocell Therapeutics Corp | 0.00 | -8.98m | 3.79m | 4.00 | -- | 3.36 | -- | -- | -1.66 | -1.66 | 0.00 | 0.196 | 0.00 | -- | -- | 0.00 | -440.01 | -- | -- | -- | -- | -- | -- | -- | -- | -7.20 | 0.00 | -- | -- | -- | -200.20 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.03m | 3.80m | 3.00 | -- | -- | -- | -- | -1.83 | -1.83 | 0.00 | 0.9986 | 0.00 | -- | -- | 0.00 | -139.98 | -104.18 | -163.33 | -111.05 | -- | -- | -- | -- | -- | -563.88 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -3.45m | 4.00m | 5.00 | -- | 0.1969 | -- | -- | -3.89 | -3.89 | 0.00 | 14.99 | 0.00 | -- | -- | 0.00 | -5.54 | -40.33 | -6.89 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Azitra Inc | 408.20k | -9.96m | 4.00m | 10.00 | -- | 0.292 | -- | 9.81 | -12.12 | -12.12 | 0.1151 | 1.80 | 0.0595 | -- | 1.83 | 40,820.00 | -145.30 | -- | -194.72 | -- | -- | -- | -2,440.46 | -- | -- | -- | 0.0191 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| Genprex Inc | 0.00 | -26.14m | 4.01m | 26.00 | -- | 0.9116 | -- | -- | -16.04 | -16.04 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -232.21 | -92.06 | -318.88 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| Tron Pharmaceuticals Inc | 1.01m | -549.47k | 4.05m | 50.00 | -- | -- | -- | 4.01 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Weed Inc | 0.00 | 57.30k | 4.07m | 2.00 | 64.71 | 541.88 | 47.12 | -- | 0.0005 | 0.0005 | 0.00 | 0.00006 | 0.00 | -- | -- | 0.00 | 6.00 | -385.93 | -- | -822.37 | -- | -- | -- | -- | -- | -46.08 | 0.944 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
Data as of Nov 11 2024. Currency figures normalised to Lixte Biotechnology Holdings Inc's reporting currency: US Dollar USD
8.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hightower Advisors LLCas of 30 Jun 2024 | 99.43k | 4.42% |
| FNY Capital Management LPas of 30 Sep 2024 | 71.64k | 3.19% |
| Ethos Financial Group LLCas of 30 Sep 2024 | 24.81k | 1.10% |
| Tower Research Capital LLCas of 30 Jun 2024 | 3.22k | 0.14% |
| UBS Securities LLCas of 30 Jun 2024 | 345.00 | 0.02% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 309.00 | 0.01% |
| Wells Fargo Bank, NA (Private Banking)as of 30 Jun 2024 | 0.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
